Stifel Financial Corp Purchases New Shares in Hims & Hers Health, Inc. (NYSE:HIMS)

Stifel Financial Corp bought a new stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 10,644 shares of the company's stock, valued at approximately $257,000.

Other hedge funds have also recently modified their holdings of the company. Means Investment CO. Inc. raised its position in Hims & Hers Health by 23.5% during the 4th quarter. Means Investment CO. Inc. now owns 50,040 shares of the company's stock valued at $1,210,000 after purchasing an additional 9,508 shares in the last quarter. Raymond James Financial Inc. purchased a new position in shares of Hims & Hers Health during the fourth quarter valued at $18,048,000. State of Alaska Department of Revenue bought a new stake in shares of Hims & Hers Health in the fourth quarter valued at about $2,628,000. Pacer Advisors Inc. bought a new stake in shares of Hims & Hers Health in the fourth quarter valued at about $374,000. Finally, Louisiana State Employees Retirement System purchased a new stake in Hims & Hers Health in the fourth quarter worth about $2,234,000. Institutional investors own 63.52% of the company's stock.

Insider Buying and Selling

In related news, COO Melissa Baird sold 33,333 shares of the firm's stock in a transaction on Monday, April 21st. The shares were sold at an average price of $25.78, for a total transaction of $859,324.74. Following the completion of the transaction, the chief operating officer now owns 805,083 shares of the company's stock, valued at $20,755,039.74. This trade represents a 3.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Andrew Dudum sold 50,000 shares of the stock in a transaction dated Tuesday, April 29th. The stock was sold at an average price of $36.39, for a total value of $1,819,500.00. Following the sale, the chief executive officer now directly owns 92,103 shares in the company, valued at $3,351,628.17. This represents a 35.19% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 563,973 shares of company stock worth $21,951,757 in the last 90 days. Insiders own 13.71% of the company's stock.

Analyst Ratings Changes

A number of research analysts have commented on the stock. Truist Financial cut their target price on shares of Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating on the stock in a research report on Thursday, April 10th. Needham & Company LLC reissued a "buy" rating and issued a $61.00 price objective on shares of Hims & Hers Health in a research note on Tuesday, May 6th. Leerink Partners upped their target price on Hims & Hers Health from $24.00 to $40.00 and gave the stock a "market perform" rating in a report on Tuesday, February 25th. TD Cowen downgraded Hims & Hers Health from a "buy" rating to a "hold" rating and cut their price target for the company from $44.00 to $30.00 in a report on Tuesday, April 29th. Finally, UBS Group reissued a "mixed" rating on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have given a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $37.67.

Hims & Hers Health Price Performance

NYSE HIMS traded up $5.87 during trading on Friday, hitting $64.45. The company's stock had a trading volume of 50,717,275 shares, compared to its average volume of 19,277,233. Hims & Hers Health, Inc. has a fifty-two week low of $13.47 and a fifty-two week high of $72.98. The company has a market cap of $14.43 billion, a PE ratio of 146.47 and a beta of 1.84. The business's 50 day simple moving average is $34.85 and its 200-day simple moving average is $33.40.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its earnings results on Monday, May 5th. The company reported $0.20 EPS for the quarter, topping analysts' consensus estimates of $0.12 by $0.08. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company had revenue of $586.01 million during the quarter, compared to analysts' expectations of $535.21 million. During the same period last year, the business earned $0.05 EPS. Hims & Hers Health's revenue for the quarter was up 110.7% on a year-over-year basis. Analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.